GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jenscare Scientific Co Ltd (HKSE:09877) » Definitions » ROA %

Jenscare Scientific Co (HKSE:09877) ROA % : -28.56% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Jenscare Scientific Co ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Jenscare Scientific Co's annualized Net Income for the quarter that ended in Dec. 2023 was HK$-428.72 Mil. Jenscare Scientific Co's average Total Assets over the quarter that ended in Dec. 2023 was HK$1,501.08 Mil. Therefore, Jenscare Scientific Co's annualized ROA % for the quarter that ended in Dec. 2023 was -28.56%.

The historical rank and industry rank for Jenscare Scientific Co's ROA % or its related term are showing as below:

HKSE:09877' s ROA % Range Over the Past 10 Years
Min: -80.31   Med: -44.54   Max: -26.51
Current: -26.51

During the past 4 years, Jenscare Scientific Co's highest ROA % was -26.51%. The lowest was -80.31%. And the median was -44.54%.

HKSE:09877's ROA % is ranked worse than
70.77% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: -1.84 vs HKSE:09877: -26.51

Jenscare Scientific Co ROA % Historical Data

The historical data trend for Jenscare Scientific Co's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jenscare Scientific Co ROA % Chart

Jenscare Scientific Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROA %
-80.31 -58.80 -30.28 -26.66

Jenscare Scientific Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROA % Get a 7-Day Free Trial -19.66 -10.75 -52.25 -24.42 -28.56

Competitive Comparison of Jenscare Scientific Co's ROA %

For the Medical Devices subindustry, Jenscare Scientific Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jenscare Scientific Co's ROA % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jenscare Scientific Co's ROA % distribution charts can be found below:

* The bar in red indicates where Jenscare Scientific Co's ROA % falls into.



Jenscare Scientific Co ROA % Calculation

Jenscare Scientific Co's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-406.597/( (1598.386+1451.545)/ 2 )
=-406.597/1524.9655
=-26.66 %

Jenscare Scientific Co's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-428.722/( (1550.607+1451.545)/ 2 )
=-428.722/1501.076
=-28.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Jenscare Scientific Co  (HKSE:09877) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-428.722/1501.076
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-428.722 / 0)*(0 / 1501.076)
=Net Margin %*Asset Turnover
=N/A %*0
=-28.56 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Jenscare Scientific Co ROA % Related Terms

Thank you for viewing the detailed overview of Jenscare Scientific Co's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Jenscare Scientific Co (HKSE:09877) Business Description

Traded in Other Exchanges
N/A
Address
No. 777 Binhai 4th Road, Block 5, B Area, Hangzhou Bay New Area, Zhejiang Province, Ningbo, CHN
Jenscare Scientific Co Ltd is a China-based company mainly engaged in the manufacturing and research and development of medical devices. The company develops interventional products for the treatment of structural heart disease. The company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure.
Executives
Shanghai Jiachen Investment Co.,ltd 2201 Interest of corporation controlled by you
Li Hui 2501 Other
Lv Shiwen 2501 Other
Ningbo Dixiang Venture Capital Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Shidi Industrial Development Co., Ltd. 2501 Other
Ningbo Sangdi Investment Management L.p. (limited Partnership) 2101 Beneficial owner
Ningbo Linfeng Biotechnology Co., Ltd. 2101 Beneficial owner
Pan Fei 2201 Interest of corporation controlled by you
Hainan Yize Medical Technology Co., Limited 2201 Interest of corporation controlled by you
Hainan Maidi Enterprise Management L.p. (limited Partnership) 2101 Beneficial owner
Hainan Hualing Investment L.p. (limited Partnership) 2101 Beneficial owner
Hangzhou Chende Investment Partnership (limited Partnership) 2101 Beneficial owner
Ningbo Mukang Venture Capital Partnership (limited Partnership)
Li Hui

Jenscare Scientific Co (HKSE:09877) Headlines

No Headlines